Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PLEC | Q15149 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575532 | 0.86 | MAPK1 (0.45) | KDM4EALDH1A1HSD17B10MAPK1PARP10 | |
| SCHEMBL7515441 | 0.86 | HSD17B10 (0.42) | KDM4EALDH1A1HSD17B10MAPK1PARP10 | |
| SCHEMBL16863983 | 0.86 | HSD17B10 (0.42) | KDM4EALDH1A1HSD17B10MAPK1PARP10 | |
| SCHEMBL14235937 | 0.85 | PARP1 (0.50) | KDM4EALDH1A1HSD17B10MAPK1PARP10 | |
| SCHEMBL2858379 | 0.84 | HSD17B10 (0.41) | KDM4EALDH1A1HSD17B10MAPK1PARP10 | |
| SCHEMBL6112695 | 0.83 | HRH4 (0.46) | KDM4EALDH1A1HSD17B10MAPK1PARP10 | |
| SCHEMBL30269683 | 0.83 | GAA (0.61) | KDM4EALDH1A1HSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL4160955 | 0.83 | CREBBP (0.61) | KDM4EALDH1A1HSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL3131960 | 0.83 | GAA (0.61) | KDM4EALDH1A1HSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL13816866 | 0.82 | PARP1 (0.47) | KDM4EALDH1A1HSD17B10MAPK1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5599629-A | EPOXY RESIN HAVING AT LEAST ONE GLYCIDYL AMINE GROUP AND THREE OR MORE EPOXIDE GROUPS PER MOLECULE, AROMATIC AMINE HARDENER SUBSTITUTED WITH ELECTRON WITHDRAWING GROUP IN SPECIFIED STOICHIOMETRY | AMOCO CORPORATION (US) | 1997-02-04 | — | — | US | claimed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-7396935-B2 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| EP-1618092-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1617840-A2 | PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050159424-A1 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-21 | — | — | US | disclosed |
| US-20050004176-A1 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004099156-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098518-A2 | PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| US-5599629-A | EPOXY RESIN HAVING AT LEAST ONE GLYCIDYL AMINE GROUP AND THREE OR MORE EPOXIDE GROUPS PER MOLECULE, AROMATIC AMINE HARDENER SUBSTITUTED WITH ELECTRON WITHDRAWING GROUP IN SPECIFIED STOICHIOMETRY | AMOCO CORPORATION (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | KDM4E 1412/4885ALDH1A1 2838/4885HSD17B10 3261/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | KDM4E 3344/4885ALDH1A1 2289/4885HSD17B10 2821/4885 |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | MAPK1, MAPK3, TNF | KDM4E 1524/4885ALDH1A1 4289/4885HSD17B10 4817/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | KDM4E 1412/4885ALDH1A1 2838/4885HSD17B10 3261/4885 |
| US-20050159424-A1 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | MAPK6, CDK6, GRK6 | KDM4E 2303/4885ALDH1A1 2758/4885HSD17B10 3198/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | KDM4E 1412/4885ALDH1A1 2838/4885HSD17B10 3261/4885 |
| US-20050004176-A1 | Pyrazole-amide compounds useful as kinase inhibitors | MAP3K1, MAP3K5, MAP3K7 | KDM4E 3013/4885ALDH1A1 2171/4885HSD17B10 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.